IPSEN (OTCMKTS:IPSEY) Shares Gap Down – What’s Next?

IPSEN (OTCMKTS:IPSEY)’s stock price gapped down before the market opened on Friday. The stock had previously closed at $42.4080, but opened at $40.6550. IPSEN shares last traded at $40.6550, with a volume of 1,408 shares traded.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. HC Wainwright reiterated a “buy” rating on shares of IPSEN in a report on Tuesday, June 30th. Jefferies Financial Group lowered IPSEN from a “hold” rating to a “moderate sell” rating in a research report on Sunday, August 2nd. Barclays upgraded IPSEN from a “strong sell” rating to a “hold” rating in a research note on Thursday, September 17th. Finally, Zacks Research upgraded IPSEN to a “hold” rating in a report on Friday, May 29th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, IPSEN has an average rating of “Hold”.

IPSEN Stock Performance

The stock’s 50 day moving average is $46.15 and its two-hundred day moving average is $46.59.

About IPSEN

Ipsen SA is a France-based biopharmaceutical company that develops and commercializes specialty medicines for serious diseases. Its primary focus areas are oncology, rare diseases and neuroscience, with research and development activities aimed at addressing conditions that often have limited treatment options.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and endocrine disorders, Dysport (abobotulinumtoxinA) for selected neurological and muscular conditions, and oncology treatments including Cabometyx and Onivyde.